Medical Oncology at St. Francis: physicians
Dr. Irvin joined the Bon Secours Cancer Institute from faculty at the University of North Carolina where he developed a specialty in breast cancer. At North Carolina, he led a nationally recognized clinical trial on pharmacogenetic dosing of tamoxifen. His research interests include overcoming endocrine resistance in breast cancer, triple-negative breast cancer, and breast cancer in young women. He attended the University of Virginia for his undergraduate degree and received his medical degree from Virginia Commonwealth University School of Medicine. He completed his internal medicine residency from Virginia Commonwealth University. From there, Dr. Irvin completed a hematology and oncology fellowship at the University of North Carolina. Dr. Irvin is board certified by the American Board of Internal Medicine in Internal Medicine, Medical Oncology, and Hematology. For the Bon Secours Cancer Institute, Dr. Irvin is the Director of Clinical Research and the Physician Site Leader for Medical Oncology. Originally from Richmond, Dr. Irvin, his wife, and three children are excited to be home in Virginia.
Books and chapters:
Irvin W, Muss H. Clinical Trials in the Elderly. In: Naeim, Reubin, and Ganz eds. Management of Cancer in the Older Patient. Philadelphia, PA: Elsevier Saunders, 2012, p. 103-108.
Irvin W, Amos K. Chapter 83: Selection of patients for therapy. In: Kuerer, ed. Kuerer’s Breast Surgical Oncology. New York, NY: McGraw-Hill Professional, 2010, p.867-875.
Irvin W, Carey LA. Breast Cancer. In: Kilzer N, ed. World Book Encyclopedia. (Electronic Product). Chicago, IL: World Book Publishing; 2008, 591.
Paoletti C, Li Y, Muñiz MC, Kidwell KM, Aung K, Thomas DG, Brown ME, Abramson VG, Irvin WJ Jr., Lin NU, Liu MC, Nanda R, Nangia JR, Storniolo AM, Traina TA, Vaklavas C, Van Poznak CH, Wolff AC, Forero-Torres A, Hayes DF; Translational Breast Cancer Research Consortium (TBCRC). Significance of Circulating Tumor Cells in metastatic triple negative breast cancer patients within a randomized, phase II trial TBCRC 019. Clin Cancer Res. 2015 Jun 15; 21 (12): 2771-9. Epub 2015 Mar 16. PMID 25779948.
Hertz DL, Snavely AC, McLeod HL, Walko CM, Ibrahim JG, Anderson S, Weck KE, Magrinat G, Olajide O, Moore S, Raad R, Carrizosa DR, Corso S, Schwartz G, Pepperson JM, Evans JP, Jones DR, Desta Z, Flockhart DA, Carey LA, Irvin WJ Jr. Br J Clin Pharmacol. 2015 Apr 24. Epub ahead of print. PMID 25907378.
Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ Jr., Krontiras H, De Los Santos JF, Haluska P, Grizzle W, Meyers RM, Wolff AC; Translational Breast Cancer Research Consortium (TBCRC). TBCRC 019: An phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with metastatic triple negative breast cancer. Clin Cancer Res. 2015 Jun 15; 21 (12): 2722-9; Epub 2015 Mar 16. PMID 25779953.
Dr. Raddin graduated Phi Beta Kappa from the University of Virginia, where he studied as an Echols Scholar. He went on to earn his medical degree and complete his residency in internal medicine at Virginia Commonwealth University, where he was elected to the Alpha Omega Alpha Honor Medical Society. Dr. Raddin completed his hematology and oncology fellowship training at the University of North Carolina, serving as chief fellow during his final year. While at UNC, he led initiatives to improve the quality of care that patients with cancer receive and was involved in carrying out clinical trials, including serving as principal investigator for a study evaluating supportive care for patients with cancer. Dr. Raddin is board certified in internal medicine, hematology, and medical oncology. When not at work, he enjoys spending time with his wife and two young sons in his hometown of Richmond.
Sarah attended the University of Virginia's College at Wise where she was a member of Sigma Zeta National Honor Society and graduated with a baccalaureate degree in biology. She went on to study nursing at Virginia Commonwealth University as a member of Sigma Theta Tau International Honor Society for Nursing. While attending VCU, Sarah worked as a patient care tech and registered nurse in the emergency room at Bon Secours facilities. She received both her baccalaureate and master's degree in nursing with honors from VCU. She is board certified by the American Nurses Credentialing Center as a family nurse practitioner. Sarah has worked with oncology patients since 2010 and is dedicated to providing compassionate care to her patients. As a Chester native, she enjoys spending time around the area with her husband and young son.